Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study

Uwe Liebchen¹,², Hanna Salletmeier¹, Simon Kallee¹, Christina Scharf¹, Lucas Huebner¹, Alexandra Weber² & Michael Zoller¹

The aim of this study was to investigate optimal loading doses prior to continuous infusion of meropenem in critically ill patients. A previously published and successfully evaluated pharmacokinetic model of critically ill patients was used for stochastic simulations of virtual patients. Maintenance doses administered as continuous infusion of 1.5–6 g/24 h with preceding loading doses (administered as 30 min infusion) of 0.15–2 g were investigated. In addition to the examination of the influence of individual covariates, a best-case and worst-case scenario were simulated. Dosing regimens were considered adequate if the 5th percentile of the concentration–time profile did not drop at any time below four times the S/I breakpoint (= 2 mg/L) of Pseudomonas aeruginosa according to the EUCAST definition. Low albumin concentrations, high body weight and high creatinine clearances increased the required loading dose. A maximum loading dose of 0.33 g resulted in sufficient plasma concentrations when only one covariate showed extreme values. If all three covariates showed extreme values (= worst-case scenario), a loading dose of 0.5 g was necessary. Higher loading doses did not lead to further improvements of target attainment. We recommend the administration of a loading dose of 0.5 g meropenem over 30 min immediately followed by continuous infusion.

Abbreviations
S/I  Susceptible/susceptible with increased exposure
EUCAST  European Committee on Antimicrobial Susceptibility Testing
PK/PD  Pharmacokinetic/Pharmacodynamic
fT > MIC  Time of the free drug above the minimal inhibitory concentration
CLCR  Clearance creatinine according to Cockcroft and Gault
LD  Loading dose

Meropenem is regularly used to treat life-threatening infections in critically ill patients, as it covers a broad spectrum of pathogens and shows a bactericidal mechanism of action¹. Prompt initiation of an effective therapy is imperative, as each hour of delay increases mortality by approximately 7%². In common with all beta-lactams, meropenem exerts its activity via a time-dependent mechanism, i.e. the relevant pharmacokinetic/pharmacodynamic (PK/PD) index is the time of the free concentration exceeding the minimum inhibitory concentration of the pathogen (fT > MIC)³. Continuous infusion offers theoretical advantages to improve this index: Roberts et al. detected in a meta-analysis a lower in-hospital mortality with continuous infusion compared to intermittent infusion⁴. However, administering meropenem as a continuous infusion and starting with the maintenance rate would lead to a period below the MIC in the increasing part of the concentration–time profile. This should be avoided especially at the beginning of a course of treatment, when adequate antibiotic exposure is key⁵. In order to raise the concentration as quickly as possible above the MIC, the administration of an initially higher dose, i.e. a "loading dose", is recommended⁶. However, according to previously published guidelines on the optimization of the treatment with beta lactam antibiotics in critically ill patients, there is currently no consensus

¹Department of Anesthesiology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377 Munich, Germany. ²Department of Hospital Pharmacy, University Hospital, LMU Munich, Marchioninstr. 15, 81377 Munich, Germany. *email: uwe.liebchen@med.uni-muenchen.de
on the amount of a loading dose which should be used in terms of rational antibiotic therapy for meropenem with subsequent continuous infusion.

Therefore, this study aimed to identify the optimal loading dose when meropenem is subsequently administered as continuous infusion in critically ill patients. For this purpose, a simulation study was conducted based on data of a prospective PK study.

Material and methods
Pharmacokinetic model. A previously published two compartment model with first-order elimination of critically ill patients was employed for simulation. This model was recently successfully evaluated and revealed a neglectable bias. Briefly, this model is based on a prospective observational study in a population of 48 critically ill patients with severe infections and dense PK sampling (n = 1376) over 4 days. All patients were administered meropenem standard doses three times daily as a short infusion over 30 min. For further information regarding the original data, please refer to Ehmann et al. Based on this study, a nonlinear-mixed effect model was developed including three covariates: creatinine clearance (CLCR) according to Cockcroft and Gault as a covariate on meropenem clearance, total body weight on the central volume of distribution and serum albumin concentration on the peripheral volume of distribution, implemented as piecewise linear, power and linear relationship, respectively. Alterations in albumin concentrations and body weight influence the volume of distribution of meropenem according to the employed PK model, i.e. low albumin concentrations lead to an increased peripheral volume of distribution, while a higher body weight leads to a higher central volume of distribution.

Pharmacokinetic/pharmacodynamic target. A PK/PD target of 100% T > 4xMIC was selected, which has recently been associated with maximizing therapeutic effect and minimizing the spread of resistance of beta-lactams. Due to the negligible protein binding of meropenem, only total meropenem concentrations were considered. Given the non-achievability of target attainment in the very first period of the administration of the loading dose (increasing part of the concentration-time profile during the infusion of the loading dose), we ignored the first 30 min of infusion. Since there is no MIC available at the start of therapy in the case of empirical therapy, we used the unspecific S/I breakpoint (= 2 mg/L) for Pseudomonas aeruginosa provided by the EUCAST. Dosing regimens were considered adequate if the 5th percentile of the concentration-time profile did not drop below 8 mg/L at any time after administration of the loading dose, i.e. the PK/PD target of 100% T > 4xMIC was achieved.

Simulations. All simulations were performed using the R-package mrgsolve (R version 4.0.2, CRAN.R-project.org). Three daily doses (1.5 g, 3 g, 6 g) were simulated stochastically (nsimulations = 1000). Daily maintenance doses of 1.5 g were administered for patients with CLCR ≤ 30 mL/min, 3 g for CLCR > 30 mL/min and ≤ 80 mL/min and 6 g for patients with CLCR > 80 mL/min in order to achieve sufficient steady state concentrations (based on)..

Every daily dose was combined with six different loading doses (0.15 g, 0.25 g, 0.33 g, 0.5 g, 1 g, 2 g), with the loading dose being administered over 30 min and the daily dose administered immediately thereafter as a continuous infusion. Four different scenarios were investigated:

Scenario 1: simulation of patients with varying renal function (CLCR 0–160 mL/min, step-size: 10 mL/min), albumin and body weight were fixed (2.8 g/dL, 70 kg).

Scenario 2: simulation of patients with varying albumin levels (1–4 g/dL, step-size: 0.25 g/dL), CLCR and body weight were fixed (80 mL/min, 70 kg).

Scenario 3: simulation of patients with varying body weight (50–150 kg, step-size: 10 kg), CLCR and albumin were fixed (80 mL/min, 2.8 g/dL).

Scenario 4: simulation of a best- and worst-case scenario, i.e. in the worst case scenario a patient was simulated with CLCR of 160 mL/min, albumin of 1 g/dL and body weight of 150 kg (daily dose 6 g). In the best-case scenario a patient was simulated with CLCR of 0 mL/min, albumin of 4 g/dL and body weight of 50 kg (daily dose 1.5 g).

Results
Influence of creatinine clearance. First, the influence of the renal function was evaluated. A loading dose of 0.15 g revealed insufficient minimum concentrations for all simulated regimens and CLCR values and led to a delay until adequate concentrations were achieved. A loading dose of 0.25 g was not sufficient for patients with all examined values of CLCR, as the minimum value of the 5th percentile of the concentration-time profile was below the 8 mg/L limit for very high CLCR values (e.g. CLCR 160 mL/min: 7.93 mg/L). A loading dose of 0.33 g revealed adequate concentrations for all patients by being clearly above the threshold of 8 mg/L for 100% of the time (lowest 5th percentile: 9.0 mg/L for patients with CLCR 160 mL/min). Figure 1 illustrates the influence of the renal function. Figure 2 shows the influence of different loading doses graphically.

Influence of albumin-concentrations. Higher loading doses were needed in patients with low albumin concentrations compared to patients with high albumin concentrations. As described in Scenario 1 (patients with varying kidney function), a loading dose of 0.15 g resulted in a delayed achievement of adequate concentrations for all examined albumin-concentrations. Using a loading dose of 0.25 g, sufficient plasma concentrations could be achieved in some, but not all cases immediately after infusion of the loading dose. For example, a patient with a loading dose of 0.25 g, a CLCR of 80 mL, a body weight of 70 kg, a daily dose of 3 g and an albumin concentration of 1 g/dL achieved a median minimum concentration of 9.1 mg/L (5th percentile: 7.40 mg/L). In contrast, a patient with the same covariates but an albumin concentration of 4 g/dL achieved median minimum
concentrations of 11.5 mg/L (5th percentile: 9.5 mg/L). However, with a loading dose of 0.33 g, all patients showed plasma concentrations clearly above the threshold of 8 mg/L for 100% of the time.

**Influence of body weight.** Similar to the albumin-scenario, body weight influenced the required loading dose; higher loading doses are needed in patients with higher body weight. A loading dose of 0.15 g led to insufficient post-loading dose plasma concentrations. Sufficient concentrations could partly be achieved with a...
loading dose of 0.25 g: a patient with a loading dose of 0.25 g, a CLCR of 80 mL/min, a body weight of 150 kg, a daily dose of 3 g and an albumin concentration of 2.8 g/dL achieved only a minimum median concentration of 8.8 mg/L (5th percentile: 6.9 mg/L), while a patient with the same CLCR and albumin concentration but a body weight of 50 kg achieved concentrations of 10.8 mg/L (5th percentile: 8.5 mg/L). With a loading dose of 0.33 g, all patients showed concentrations clearly above the threshold of 8 mg/L for 100% of the time.

Best-case/worst-case scenario. Without a loading dose, it would take 3.4 and 2.6 h for the 5th percentile to reach the target concentration in the best- and worst-case scenarios, respectively. The accelerated achievement of the target concentration in the worst-case scenario can be explained by the higher infusion rate (6 g/24 h vs. 1.5 g/24 h). All loading doses of 0.25 g or higher led to the achievement of the PK/PD target in the best-case scenario. In contrast, in the worst-case scenario, a loading dose of 0.25 g showed insufficient concentrations in the beginning: the 5th percentile of the minimum of the concentration-time profile fell clearly below the target concentration of 8 mg/L (median: 8.66 mg/L, 5th percentile: 6.6 mg/L). Also, a loading dose of 0.33 g showed a short period when the 5th percentile of the concentration-time profile dropped below the target range of 8 mg/L (7.8 mg/L). Loading doses greater or equal to 0.5 g revealed no drops of the concentrations at any timepoint below 8 mg/L and were therefore considered adequate in the worst-case scenario. Figure 3 illustrates the best- and worst-case scenario.

Discussion
The administration of a loading dose before the initiation of continuous infusion is generally accepted and recommended for beta-lactams. In the majority of studies investigating continuous infusion loading doses were administered, including the large multicenter studies BLISS and BLING II. This practice is supported by a significant mortality reduction when loading doses are administered compared to no loading doses according to a large meta-analysis by Vardakas et al. However, in previous studies with continuous infusion of meropenem, heterogeneous loading doses of 0.5–2 g were administered, indicating that reliable recommendations on the optimal dose are missing. Guilhaumou et al. recommended in the absence of consensus in their guideline on optimizing beta-lactam therapy in critically ill patients administering a loading dose identical to that used in the case of discontinuous administration.

In the present study, we extensively analyzed which amount of a loading dose should be administered to achieve sufficient concentrations at the onset of continuous infusion therapy for meropenem. For this purpose, we followed a simulation approach based on a previously published PK model. The employed model was developed based on densely collected samples and a high number of heterogenous critically ill patients. The advantage
of a simulation-based approach compared to a prospective study is, besides the lower costs, the possibility to investigate an unlimited number of possible combinations of loading doses and infusion rates. Furthermore, especially when investigating a short time interval of drugs with a short half-life (here: time when loading dose of meropenem is administered), small protocol deviations (e.g. sample collection 5 min to late) would lead to massive inaccuracies of the measured concentrations. It should be noted as a strength of this study that the model employed can be considered valid since the model was evaluated externally showing negligible bias. The evaluation of the PK model revealed a negligibly small underestimation of the measured concentrations (−0.84 mg/L).

In the context of this simulation study, this would mean that the actual concentrations would tend to be slightly higher than the predicted concentrations indicating a further safety margin (towards subtherapeutic exposure). A previous study by Delattre et al. also used a simulation-based approach to identify the optimal loading dose of four beta-lactams including meropenem. Unfortunately, this study did not investigate which loading doses should be administered if continuous infusion is immediately started after the loading dose (only intermittent dosing regimens were investigated). The authors suggested a loading dose of 2 g meropenem, administered over 30 min, with the next dose 6 h later. Therefore, the loading dose proposed in the study by Delattre et al. is significantly higher than the one identified in our study. However, it should be assessed in the circumstance that concentrations continue to drop until the next dose is administered 6 hours later, which is not the case if the infusion is administered at the maintenance rate immediately after the end of the loading dose.

Maintenance doses were adjusted for renal function in our study. This approach corresponded in all cases with steady state concentrations in the therapeutic range and most closely reflects actual practice in the administration of meropenem in critically ill patients. While CLCR is decisive for the required continuous infusion rate, albumin and body weight (as covariates on the volumes of distribution) are relevant for the loading dose. A low loading dose of 0.33 g was sufficient when only one of the three investigated covariates (CLCR, albumin, body weight) showed extreme values. However, in a worst-case scenario, a loading dose of 0.5 g resulted in adequate plasma concentrations. This loading dose of 0.5 g was previously described as adequate prior to continuous infusion in simulations, is commercially available and was used in a clinical context. Toxic concentrations are not expectable from this loading dose. Higher loading doses do not promise any further advantage in target attainment, but potentially might lead to toxic effects. Neurotoxicity and nephrotoxicity have been reported with high trough levels of meropenem during intermittent infusion, however, no data on toxic peak levels are available to date.

This study examines purely the relationship between the attainment of a defined PK/PD target and the amount of a loading dose. However, the investigation of clinical outcomes related to PK/PD targets should be further addressed in future studies.

Conclusions
This is the first study that investigated optimal loading doses with subsequent continuous infusion of meropenem in critically ill patients. Administration of a loading dose of 0.5 g over 30 min immediately followed by continuous infusion promises instantaneous achievement of sufficient target concentrations. Therefore, we recommend the application of 0.5 g meropenem as a loading dose for all critically ill patients. Higher loading doses do not lead to further improvements in target attainment.

Data availability
Code is available via Email request to uwe.liebchen@med.uni-muenchen.de.

Received: 17 June 2021; Accepted: 5 August 2021
Published online: 26 August 2021

References
1. Baldwin, C. M., Lyseng-Williamson, K. A. & Keam, S. J. Meropenem: A review of its use in the treatment of serious bacterial infections. Drugs 68, 803–838 (2008).
2. Kumar, A. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34, 1589–1596 (2006).
3. Craig, W. A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22, 89–96 (1995).
4. Roberts, J. A. et al. Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am. J. Respir. Crit. Care Med. 194, 681–691 (2016).
5. Ferrer, R. et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: Results from a guideline-based performance improvement program. Crit. Care Med. 42, 7 (2014).
6. Guilhaumou, R. et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFT) and the French Society of Anesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation—SFAR). Crit. Care 23, 104 (2019).
7. Ehmann, L. et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. Int. J. Antimicrob. Agents https://doi.org/10.1016/j.ijantimicag.2019.06.016 (2019).
8. Liebchen, U. et al. Evaluation of the merorisk calculator, a user-friendly tool to predict the risk of meropenem target non-attainment in critically ill patients. Antibiotics 10, 468 (2021).
9. Cockcroft, D. W. & Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31–41 (1976).
10. Schießer, S. et al. Measurement of free plasma concentrations of beta-lactam antibiotics: An applicability study in ICU patients. Ther Drug Monit https://doi.org/10.1097/FTD.0000000000000827 (2020).
11. Liebchen, U. et al. Meropenem, cefepime, and piperacillin protein binding in patient samples. Ther. Drug Monit. 42, 129–132 (2020).
12. European Committee on Antimicrobial Susceptibility Testing (EUCAST): Breakpoint tables for interpretation of MICs and zone diameters Version 11.0, 2021. Accessed 29th February 2021. http://www.eucast.org/clinical_breakpoints/.
13. Abdul-Aziz, M. H. et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): A prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. *Intensive Care Med.* **42**, 1533–1545 (2016).
14. Dulhunty, J. M. et al. A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis. *Am. J. Respir. Crit. Care Med.* **192**, 1298–1305 (2015).
15. Vardakas, K. Z., Voulgaris, G. L., Malaaros, A., Samonis, G. & Falagas, M. E. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: A systematic review and meta-analysis of randomised trials. *Lancet. Infect. Dis.* **18**, 108–120 (2018).
16. Zhao, H.-Y. et al. Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: A prospective randomized pilot study. *Chin. Med. J.* **130**, 1139–1145 (2017).
17. Jamal, J.-A. et al. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. *Int. J. Antimicrob. Agents* **45**, 41–45 (2015).
18. Chytra, I. et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: A randomized open-label controlled trial. *Crit. Care* **16**, R113 (2012).
19. Alhodzic, D. et al. Impact of inaccurate documentation of sampling and infusion time in model-informed precision dosing. *Front. Pharmacol.* **11**, 172 (2020).
20. Delattre, I. K. et al. What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling. *Int. J. Antimicrob. Agents* **56**, 106113 (2020).
21. Chiriac, U. et al. Personalized β-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment. *Medicine* **100**, e26253 (2021).
22. Imani, S., Buscher, H., Marriott, D., Gentili, S. & Sandaradura, I. Too much of a good thing: A retrospective study of β-lactam concentration–toxicity relationships. *J. Antimicrob. Chemother.* **72**, 2891–2897 (2017).

**Acknowledgements**

Ferdinand Weinelt is credited for stimulating discussions on the topic.

**Author contributions**

U.L. conceived the idea for the article. U.L. designed the data analysis. U.L. analyzed data. All authors discussed results. U.L. drafted the manuscript. All authors commented on and approved the manuscript. All authors read and approved the final manuscript.

**Funding**

Open Access funding enabled and organized by Projekt DEAL. This work was funded by institutional sources. UL acknowledges the funding of research by the Munich Clinician-Scientist Program.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to U.L.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021